These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 7200248)

  • 1. Catalepsy produced by long-acting neuroleptics, fluphenazine enanthate and fluphenazine decanoate, in mice.
    Yamada K; Furukawa T
    Pharmacology; 1982; 24(3):147-55. PubMed ID: 7200248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. behavior of rats and mice administered active metabolites of fluphenazine, 7-hydroxy-fluphenazine and fluphenazine-sulfoxide.
    Yamada K; Furukawa T
    Arch Int Pharmacodyn Ther; 1980 Nov; 248(1):76-85. PubMed ID: 7194019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacological studies of long-acting phenothiazines with particular reference to fluphenazine decanoate (author's transl)].
    Chen PC
    Nihon Yakurigaku Zasshi; 1978 Oct; 74(7):871-83. PubMed ID: 570538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of a strong influence of neuroleptic decanoates on dopaminergic and GABAergic functions.
    Ossowska K; Wolfarth S
    Pol J Pharmacol; 1995; 47(2):99-107. PubMed ID: 8688897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Behavioral and electroencephalographic effects of a depot type neuroleptic fluphenazine decanoate, in rats.
    Yamamoto T; Ueki S
    J Pharmacobiodyn; 1989 Nov; 12(11):681-92. PubMed ID: 2632765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticataleptic effect of taurine: interaction with antiparkinsonian agents.
    Zebrowska-Lupina I; Porowska A
    Pol J Pharmacol Pharm; 1987; 39(4):329-35. PubMed ID: 2897118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical pharmacokinetics of the depot antipsychotics.
    Jann MW; Ereshefsky L; Saklad SR
    Clin Pharmacokinet; 1985; 10(4):315-33. PubMed ID: 2864156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical pharmacokinetics of haloperidol decanoate. Comparison with other prolonged-action neuroleptics].
    Levron JC; Ropert R
    Encephale; 1987; 13(2):83-7. PubMed ID: 2885172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of alpha-adrenergic drugs on catalepsy induced by haloperidol or fluphenazine in rats.
    Wielosz M; Kleinrok Z; Włoch K; Zebrowska-Lupina I
    Pol J Pharmacol Pharm; 1978; 30(5):653-8. PubMed ID: 35783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Haloperidol decanoate as a replacement for maintenance therapy with intramuscular fluphenazine decanoate in schizophrenia and other chronic psychoses.
    Roose K
    Acta Psychiatr Belg; 1982; 82(2):216-23. PubMed ID: 7180558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Possible neuronal mechanisms involved in neurotensin-induced catalepsy in mice.
    Shibata K; Yamada K; Furukawa T
    Psychopharmacology (Berl); 1987; 91(3):288-92. PubMed ID: 2882538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of repeated haloperidol and apomorphine administration on the development of tolerance for catalepsy and dopamine receptor hypersensitivity in mice].
    Zharkovskiĭ AM; Matvienko OA; Nurk AM
    Biull Eksp Biol Med; 1984 Oct; 98(10):444-6. PubMed ID: 6541951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double-blind comparison of haloperidol decanoate and fluphenazine decanoate effectiveness, side-effects, dosage and serum levels during a six months' treatment for relapse prevention.
    Kissling W; Möller HJ; Walter K; Wittmann B; Krueger R; Trenk D
    Pharmacopsychiatry; 1985 May; 18(3):240-5. PubMed ID: 4011672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia.
    Chouinard G; Annable L; Campbell W
    J Clin Psychopharmacol; 1989 Aug; 9(4):247-53. PubMed ID: 2570086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. D2 dopamine antisense RNA expression vector, unlike haloperidol, produces long-term inhibition of D2 dopamine-mediated behaviors without causing Up-regulation of D2 dopamine receptors.
    Davidkova G; Zhou LW; Morabito M; Zhang SP; Weiss B
    J Pharmacol Exp Ther; 1998 Jun; 285(3):1187-96. PubMed ID: 9618422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ten year outcomes of outpatients with schizophrenia on conventional depot antipsychotics: a systematic chart review.
    Uchida T; Suzuki T; Sakurai H; Tsutsumi C; Den R; Mimura M; Uchida H
    Int Clin Psychopharmacol; 2013 Sep; 28(5):261-6. PubMed ID: 23820334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of 5-hydroxytrytamine synthesis inhibitors on neuroleptic-induced catalepsy in rats.
    Sarnek J; Baran L
    Arch Immunol Ther Exp (Warsz); 1975; 23(4):511-6. PubMed ID: 1172422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Weight gain and prolactin levels in patients on long-term antipsychotic medication: a double-blind comparative trial of haloperidol decanoate and fluphenazine decanoate.
    Cookson JC; Kennedy NM; Gribbon D
    Int Clin Psychopharmacol; 1986 Jul; 1 Suppl 1():41-51. PubMed ID: 3549879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the incidence and severity of extrapyramidal side effects with fluphenazine enanthate and fluphenazine decanoate.
    Kane J; Quitkin F; Rifkin A; Klein DF
    Am J Psychiatry; 1978 Dec; 135(12):1539-42. PubMed ID: 717574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A double-blind comparative trial of the decanoates of clopenthixol and fluphenazine in the treatment of chronic schizophrenic out-patients.
    Walker CA
    Pharmatherapeutica; 1983; 3(5):289-93. PubMed ID: 6133287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.